Management of short bowel syndrome in postoperative very low birth weight infants

Olivia Mayer a, *, John A. Kerner a, b

a Lucile Packard Children’s Hospital Stanford, Palo Alto, CA, USA
b Stanford University Medical Center, Stanford, CA, USA

Keywords:
- Very low birth weight infants
- Parenteral nutrition
- Short bowel syndrome
- Enteral nutrition
- Cholestasis
- Parenteral nutrition-associated cholestasis

S U M M A R Y

Short bowel syndrome is a potentially devastating morbidity for the very low birth weight infant and family with a high risk for mortality. Prevention of injury to the intestine is the ideal, but, if and when the problem arises, it is important to have a systematic approach to manage nutrition, use pharmaceutical strategies and tools to maximize the outcome potential. Safely maximizing parenteral nutrition support by providing adequate macronutrients and micronutrients while minimizing its hepatotoxic effects is the initial postoperative strategy. As the infant stabilizes and starts to recover from that initial injury and/or surgery, a slow and closely monitored enteral nutrition approach should be initiated. Enteral feeds can be complemented with medications and supplements emerging as valuable clinical tools. Engaging a multidisciplinary team of neonatologists, gastroenterologists, pharmacists, skilled clinical nutrition support staff including registered dietitians and nutrition support nurses will facilitate optimizing each and every infant’s long term result. Promoting intestinal rehabilitation and adaptation through evidence-based practice where it is found, and ongoing pursuit of research in this rare and devastating disease, is paramount in achieving optimal outcomes.

© 2016 Elsevier Ltd. All rights reserved.

1. Introduction

Infants with a birth weight of ≤1500 g are at high risk for a variety of morbidities including necrotizing enterocolitis (NEC), ischemic injury along the length of the intestine, jejunal or ileal atresias, and gastrochisis. All of these conditions may require surgical intervention. Short bowel syndrome (SBS) in very low birth weight (VLBW) infants, those born at ≤1500 g, continues to be an unfortunate reality and is the leading cause of intestinal failure in infants [1]. Outcomes vary, and are greatly influenced by age of the injury and potential for intestinal growth, the site of the resection, presence of the ileocecal valve (ICV), the development of parenteral nutrition-associated cholestasis [PNAC, also known as parenteral nutrition-associated liver disease (PNALD)], and functionality of the gastrointestinal (GI) tract [2,3]. Management of SBS can be extremely complicated and recovery may be lifelong for some. The medical journey is further confounded by other comorbidities of prematurity, extraterine growth restriction, and congenital cardiac defects such as patent ductus arteriosus. A multidisciplinary team of neonatologists, gastroenterologists, surgeons, registered dietitians, nutrition support nurses, and pharmacists can enhance the prospect of achieving intestinal adaptation, appropriate growth and neurodevelopment [2,4].

Short bowel syndrome (SBS) is a state of malabsorption, and parenteral nutrition (PN) is needed for a prolonged period of time. Amin et al. define the need for PN as a minimum of three months whereas the Canadian Association of Pediatric Surgeons defines the need for PN as >42 days [2,5]. From 2002 to 2005, surgical SBS was recorded in 0.7% of VLBW infants by the National Institute of Child Health and Development neonatal research network centers [6]. It is extremely difficult to accurately estimate the incidence and prevalence of SBS due to the rarity of the condition and the unclear and varied definitions used to describe not only the criteria but the outcomes. Ultra-short bowel has been defined by Diamanti et al. as ≤10 cm; by Gambarara et al. as ≤20 cm; and by De Greef et al. as ≤40 cm [7–9]. SBS is most frequently the result of a surgical resection of the bowel; however, even if adequate length and anatomy of the GI tract remain intact and well perfused, it may not function properly. Function of the bowel is just as, if not more,
important as the length of the remaining bowel. Critically decreased function below what is needed for adequate absorption of fluids, electrolytes, macro- and micronutrients results in intestinal failure [10]. It is possible for some patients to be discharged on full enteral nutrition; however, for those with intestinal failure, it is highly unlikely.

The leading cause of SBS in VLBW infants is NEC [6]. Other causes include, but are not limited to: spontaneous intestinal perforation, ileal/jejunal atresias, meconium plugs and/or obstruction, gastrochisis or other congenital malformation of the intestine, malrotation, volvulus, and intussusception. Congenital short bowel syndrome is a rare disorder whereby the length of the small intestine is much less than expected for age, and is hypothesized to have a genetic origin [11]. Data gathered from 2012 by Pant et al. highlight the epidemiology and healthcare resource utilization in the USA. The statistics reflect what most of us know from experience and observation. Children with SBS have a much higher rate of mortality, longer length of hospital stay, higher hospital costs, greater post-discharge needs and costs, and demonstrate more severe illness overall [12]. Complications frequently arise and include progressive liver dysfunction and disease, bacterial overgrowth, dysmotility, renal failure, venous access difficulties, bowel obstruction, an ICV, original diagnosis of NEC or postnatal infection. Congenital short bowel syndrome is a rare disorder whereby the length of the small intestine is much less than expected for age, and is hypothesized to have a genetic origin [11]. Data gathered from 2012 by Pant et al. highlight the epidemiology and healthcare resource utilization in the USA. The statistics reflect what most of us know from experience and observation. Children with SBS have a much higher rate of mortality, longer length of hospital stay, higher hospital costs, greater post-discharge needs and costs, and demonstrate more severe illness overall [12]. Complications frequently arise and include progressive liver dysfunction and disease, bacterial overgrowth, dysmotility, renal failure, venous access difficulties, bowel obstruction, an ICV, original diagnosis of NEC or postnatal infection. The ileum absorbs fluid, vitamin B12, and bile acids, and if a significant section is removed, the jejunum has limited ability to adapt and develop some of the absorption abilities of the ileum [2]. Significant loss of the jejunum typically results in increased gastric emptying times and is associated with gastrian hypersecretion which may lead to fat malabsorption by inactivating pancreatic enzymes, acid-peptic injury, exacerbation fluid and electrolyte losses, and damage to the mucosa [2] (Fig. 1).

Premature infants have the greatest potential for intestinal growth and adaptation postoperatively. Intestinal adaptation can begin shortly after resection and lead to improved absorption of nutrients, fluids, and electrolytes. Intestinal adaptation drives overall intestinal rehabilitation by progressively attaining the ability to absorb and utilize all nutrition via an enteral route, without the need for PN support [5]. The length of the small bowel at 35 weeks of gestation is twice the length of the small bowel of a 27 week gestation [5]. Intestinal length can increase from 142 ± 22 cm at 19–27 weeks to 217 ± 24 cm at 27–35 weeks and to 304 ± 44 cm at term age [14,15]. Over time, the intestine continues to grow up to 600–700 cm which may be reached by adulthood. There have been various findings and general observations of the bowel length and outcomes. It is generally postulated that, with >15 cm of remaining small intestine with an intact ICV, or >40 cm of small intestine without an ICV, a successful outcome is likely [16]. Demehri et al. found that presence of >10% expected small bowel length, an ICV, original diagnosis of NEC or atresia predicted weaning from PN [17]. To calculate the percent of expected small bowel length, the authors measured the absolute length of remaining small bowel divided by the predicted length of small bowel based on the child’s postconceptual age × 100 [17].

Intestinal proliferation, or lengthening of the villi, and to some degree dilatation of the small-bowel lumen, may result in increased mucosal surface area following massive resection and facilitate adaptation [10].

The clinical course of SBS patients has been described in three clinical stages: acute, recovery or intermediate, and a late phase in which PN is maintained with minimal metabolic effects and/or weaning from PN is possible [2,18]. The acute phase is the immediate time following the intestinal surgery. This phase can last up to 2–3 weeks post surgery and is focussed on managing the anticipated fluid, metabolic, and electrolyte fluctuations. The goal of the acute phase is to stabilize the infant, and nutrition is provided solely via PN. Concern for infection is great and the potential compounding effects on the liver from both PN and infection are prevalent. The recovery, or intermediate stage, is the time when enteral feedings are initiated and trialed, while PN continues to be the primary mode of nutrition. If an ostomy is present, the volume of output should to be <40 mL/kg/day [2,19]. Promoting age-appropriate growth, neurodevelopment, and bone mineralization are the ideal goals for premature infant nutrition; however, these goals may be relegated to a secondary role for a period of time if calories and lipids are restricted to minimize the deleterious effects of PN on the liver. The late clinical stage of SBS is when PN volume can be weaned down as the volume of enteral nutrition (EN) is advanced. The ultimate goal for these infants is to wean off PN completely. This late stage is to maximize EN volume, absorption, and overall tolerance, while minimizing PN volume, time, and hepatotoxic effects to promote growth, neurodevelopment, and prevent nutrient deficiencies.

2. Parenteral nutrition strategies

Bypassing the GI tract to provide nutrition and fluids is life-saving in the management of SBS. Parenteral nutrition (PN) standards for VLBW infants promote growth, bone mineralization, and neurodevelopment. Infants dependent on prolonged PN are also at risk for macronutrient and micronutrient deficiencies. Balancing the need for good nutrition with the risks of prolonged PN is delicate and may be limited by vascular access issues, volume restrictions, product availability and manufacturing practices. Ideal PN macronutrient needs for VLBW provides 90–100 kcal/kg/day, 4 g amino acids/kg/day, and 2.5–3 g fat/kg/day [20]. Frequent, standardized biochemical monitoring may be needed daily postoperatively as the infant is in the acute phase, for the first 2–5 days, but when greater metabolic stability has been achieved it may be monitored 1–2 days each week. Electrolyte and micronutrient imbalances often occur, and may need more frequent adjustment in the PN.

Prolonged duration of PN and lack of enteral feeds increases the infant’s risk of developing cholestasis due to the hepatotoxic components used in PN solutions, overfeeding, soy-based intravenous (IV) lipid solutions, chronic infections, and decreased bile flow [21,22]. Delivering excessive macronutrients further exacerbates PNAC. High doses of intravenous dextrose have been shown to worsen PNAC more than IV lipids [21]. Gupta et al. found that limiting IV dextrose to a glucose infusion rate of <9.3 mg carbohydrate/kg/min in premature infants may be helpful in decreasing the incidence of PNAC [21]. Methionine excess from PN amino acids is also implicated in the development and exacerbation of PNAC [23]. IV lipids derived from soybean oil emulsions are frequently considered as the primary reason for cholestasis due to the effect of raising serum phytosterol concentrations which suppress bile flow, and providing ω-6 fatty acids, which are pro-inflammatory [21,23–25]. For more than a decade, newer intravenous fat emulsions (IVFEs) have been produced that have been
shown to reverse and even to prevent the undesired outcome of PNAC [26]. In the USA the IVFE commercially dominant products are ω-6 fatty acids. In most other areas of the world, novel IVFEs that contain a variable combination of ω-6 and ω-3 fatty acids, medium-chain triglycerides (MCTs), long-chain triglycerides, structured triglycerides, fish oil, and olive oil as sources have become standard of care [23,27]. Cessation of PN reduces and resolves chronic PNAC [28]. PN strategies used to minimize neurologic and hepatic injury in VLBW SBS infants include using Trophamine® as the amino acid product, using the lowest aluminum-containing products, decreasing the glucose infusion rate, reducing or removal of trace elements, restricting IV lipid dose, using alternative IV lipid emulsions, cycling IV lipids and/or cycling PN administration [21,24,26,29]. Reducing or eliminating nutrients from the PN will put these infants at high risk for macro- and micronutrient deficiencies.
3. Enteral nutrition strategies

The ideal outcome for infants with SBS is to thrive on enteral nutrition alone. VLBW infants are at an initial disadvantage for excellent feeding tolerance and growth due to the immaturity of the GI tract and other metabolic and immunologic complications of prematurity. SBS further compounds this struggle. Prolonged periods of time during which the GI tract is not stimulated by enteral nutrition lead to loss of structural formation of tight junctions, and deterioration of epithelial barrier function which further increases one’s risk of infection and inflammation [30]. Lack of EN and antibiotic use showed a greater influence than surgery on altering the diversity of the intestinal microbiome in a piglet model of intestinal failure [31].

Delivery of enteral nutrition is often debated in this population due to the somewhat inconclusive evidence, personal preference and experience of the practitioner. Gastric feeds are the first choice, and may be the only option if the jejunum has been resected. If an infant has a jejunostomy in place, bear in mind this further increases the risk of introducing contaminants into the small bowel which may result in small bowel bacterial overgrowth or sepsis [3]. In VLBW infants without SBS, the evidence shows that both continuous and bolus feeding strategies are suitable with their own set of risks and benefits [32,33]. Whereas bolus or intermittent feeding may result in a more physiological hormonal response, improved motility, and potentially enhanced protein accretion, bolus feeds may result in increased feeding intolerance such as emesis, firm abdomen, increase in abdominal circumference and feeding-related apneas or desaturations [32]. Using gastric residual volume as a marker for intolerance is no longer evidence-based [32]. If a portion of the intestine has been removed, the remaining intestine may be overwhelmed not only by volume, but the osmolality, and adverse events, such as emesis, diarrhea, copious ostomy output, or intestinal perforation may result. Continuous or semi-continuous feeding may improve nutrient absorption, duodenal motor function, energy efficiency, and splanchic oxygenation [10,32].

In SBS continuous feeds optimize absorption (and probably adaptation) by permitting total saturation of the transporters in the gut for 24 h/day. Enteral nutrition in SBS is usually started slowly and advanced based on stool or ostomy output (and other abdominal symptoms and signs) [5]. Initially, enteral feeding tolerance should be the primary focus in SBS infants to commence the intestinal adaptation process. Starting with trophic volumes of ~10 mL/kg/day given as 1−2 mL Q 3−6 h for 24−48 h is reasonable to assess initial tolerance and to identify possible strictures or postoperative ileus. Trophic feeds should be seen as ‘medicinal’ or ‘therapeutic’, not as a source of nutrition. As enteral feeding tolerance is demonstrated, a slow and closely monitored feeding advancement can be initiated. Typically, feeding volume is advanced by 20−30 mL/kg/day; however, for the VLBW SBS infant, initial advancement of feeds may be as slow as increasing by 1 mL every 24 h. Once the infant is tolerating at least 50−60 mL/kg/day, the advancement of feeds may be able to quicken, again, depending on the infant’s clinical picture.

Higher volumes of ostomy output typically have a negative effect on hydration status, electrolyte stability, and weight gain/growth. Conventional wisdom is that ideal ostomy output volume should be <40 mL/kg/day [2,19]. If the ostomy output is >40 mL/kg/day and the infant is gaining weight and metabolically stable, then perhaps it is fine to accept a higher ostomy output volume and continue to monitor very closely for dehydration and electrolyte alterations. More often, when ostomy output is >40 mL/kg/day, the infant is more likely to become dehydrated and experience electrolyte abnormalities. Regardless of the ostomy output volume, if infants are not growing, they are not absorbing all the nutrients they need from the feeds. Assessing ostomy output for malabsorption, by checking a fat stain, pH, and reducing substances may guide your feeding choice. Refeeding enteroostomy output through a mucous fistula has been shown to facilitate improved growth and improved EN tolerance after the bowel has been reconnected [34−37]. As with all invasive therapies, refeeding is not without risk and may lead to further complications such as perforation, intestinal bleeding, death, and ongoing PN dependence [38].

Human milk is the preferred nutrition choice for all infants, and the benefits far outweigh any perceived risks when fed to premature infants [39]. Mother’s own milk is ideal; however, if it is not available, donor human milk should be the alternative. Human milk contains properties that are non-replicable and provides advantages that infant formula cannot, such as protection from PNALD in those who receive PN >4 weeks [40]. It is reasonable to achieve full volume enteral feeds before adding fortification in order to minimize variables as EN progresses. When combined with human milk, human milk-based fortifiers will allow the infant to receive an exclusive human milk diet that meets their estimated high nutrition needs, appropriate immunotrophic and prokinetic effects such as maturation, motility, and decreased permeability, while additionally receiving immunologic components to aid their immature immune system [41,42]. When human milk-based fortifiers are not available, then a cow’s milk-based liquid formulation of human milk fortifier (HMF) should be used to meet the high nutrition needs.

If human milk is not available or tolerated, standard, intact cow’s milk protein-based formulas should be tried first [18]. Allergic reactions to cow’s milk protein and soy protein are widespread. If standard formulas are poorly tolerated, trying a partially or extensively hydrolyzed protein formula should be the next step. Hydrolyzed formulas have been shown to improve gastric emptying time as well as improve nitrogen retention by increasing serum amino acid concentrations, and most provide a higher percentage of its fat from medium chain triglycerides (MCT) [43]. Finally, if all other formulas and feeding strategies fail, try a free amino acid-based formula. These have been associated with a shorter duration of PN, decreased risk of developing a food allergy, and are generally well tolerated, despite their higher osmolality [44] (Fig. 2).

Formulas with >40% of its total fat from MCTs are preferred due to ease of absorption directly into the portal system, without the need for bile acids and micelles. Increased absorption and retention of fat leads to improved weight gain and growth. Fatty acids metabolized to short-chains have been shown to have trophic effects and aid with adaptation and absorption in both the small bowel and colon. Fat intake for VLBW is incredibly important, not just for somatic growth, but also for brain growth and development. Polyunsaturated fatty acid intake, especially docosahexaenoic acid (DHA) and arachidonic acid (ARA), is strongly correlated with positive cognitive effects in the short term; however, a recent study showed no cognitive or structural advantage to feeding VLBW infants DHA- and ARA-supplemented formula at 8 years of age [45].

Enteral nutrition strategies continue to evolve. Feeding options derived from human milk and enteral formulas striving to replicate human milk continue to emerge. Vitamin and mineral supplementation to meet micronutrient needs are standard therapy. Controversy surrounds supplemental enteral glutamine, though it has been used for years on the premise that it will aid in decreased intestinal permeability, improved tolerance to enteral feeds,
improved growth, and immune function support [46]. Probiotics —
a promising therapy in GI tract colonization, downregulation of
proinflammatory response, feeding tolerance, and growth — still
pose a risk for bacterial overgrowth and sepsis in those infants with
IV lines in place [47]. Lactobacillus bacteremia and Saccharomyces
boulardii fungemia have been reported in SBS patients with a
central venous catheter [18].

Prebiotics are a non-digestible food ingredient that has a
beneficial effect on the body. Prebiotics stimulate growth of, or
activity of, bacteria found in the colon that promote good gut health
[48]. Human milk oligosaccharide 2′-fucosyllactose (a prebiotic)
supplementation has had promising results promoting intestinal
adaptation in the murine model that showed improved weight
gain, increased microbial diversity after resection, and improved
energy processing [49]. Stimulation of enteroplasticity in the distal
intestine is improved by prebiotics by increasing glucose and
glutamine transport in the jejunum.

Lactoferrin (LF) is an anti-infective component found in whey
protein in all mammalian milk and promotes GI function by
decreasing permeability, which decreases the risk of colonization
by pathogens and decreasing infections. Human milk is a rich
source of LF. Cow’s milk LF can be isolated and produced as a
supplement. Research continues to explore a potential role for
supplementation [50].

Fig. 2. Decision tree guidelines for enteral nutrition in VLBW SBS infants post-surgical resection. HMF, Human Milk Fortifier; NPO, nothing by mouth; NG, Nasogastric Tube;
OG, Orogastric Tube; TPN, Total Parenteral Nutrition.

Please cite this article in press as: Mayer O, Kerner JA, Management of short bowel syndrome in postoperative very low birth weight infants, Seminars in Fetal & Neonatal Medicine (2016), http://dx.doi.org/10.1016/j.siny.2016.08.001
For those infants who develop PNAC, as they begin to tolerate some enteral nutrition, providing enteral fish oil supplementation may not only provide additional calories and enhance enteral feeding tolerance, it may also promote the reversal of PNAC and demonstrate improvement in liver function tests [51–54]. Based on the initial finding that administering a fish-oil-based IVFE resulted in improved liver function tests (LFT), for those infants suffering from SBS and facing prolonged PN dependence who are able to tolerate EN, enteral fish oil supplementation is a more readily available, economically sound, and physiologically beneficial therapy by reducing the inflammatory response in the GI tract and the liver [54].

4. Pharmaceutical strategies

Pharmaceutical therapies continue to be developed. Many infants will need sustained electrolyte, vitamin, and mineral supplementation as long as they still have an ostomy in place. Hypersecretion of gastric acid, a frequent postoperative challenge, may reduce the pH below the level needed for efficient fat malabsorption and may lead to peptic complications. The use of acid-suppressing medications such as proton pump inhibitors and H2 blockers is required during the malabsorption and may lead to peptic complications. The use of such agents should be used with great caution in those or high volume ostomy output in older infants and children; infections and the risk of bacterial overgrowth [10]. Given the high risk for infections from central intravenous lines, especially in patients with small-bowel bacterial overgrowth, and an immature immune system, broad-spectrum antibiotics are often used when an infant presents with fever until a specific sensitivity can be determined for targeted antibiotic therapy [10]. The use of ethanol lock therapy is increasingly being used as a long-term strategy to further lessen the risk of catheter-related bloodstream infections, which may be life-threatening in these patients [10,55]. Studies to date have only documented safety and benefit of ethanol lock therapy in infants >5 kg. Long-term care of the central line is critical to the ability to provide nutrition and appropriate medications to the patient. Standardized, evidence-based practice of flushing protocols should be utilized to prevent line occlusion, and use of thrombolytic agents should be used to restore patency [10].

Intestinal dysmotility may occur in many infants with SBS. Erythromycin increases gut motility by activating motilin receptors [2]. In a recent review, erythromycin use was associated with shorter time to full feeds, decreased duration of parenteral nutrition, and decreased incidence of cholestasis [56]. Its use was in preterm infants but not those with SBS. Ursodeoxycholic acid (UDCA) is frequently used for the treatment of PNAC. Most studies are in premature infants with an intact intestinal tract. UDCA is usually given at a dose of 20–30 mg/kg/day divided in two or three doses once patients are tolerating EN. However, it may be poorly absorbed in patients with no ileum or with significant intestinal failure, causing more diarrhea. Gallbladder stasis is from lack of enteral feedings, and a reduction of bile salts may lead to the formation of cholesterol stones. UDCA therapy is clearly recommended in this group. Early cholecystectomy for cholelithiasis should be considered. Many novel therapies have been proposed to improve bowel adaptation. Animal models have evaluated epidermal growth factor (EGF), growth hormone (GH), glucagon-like-peptide 2 (GLP-2), keratinocyte growth factor, interleukin-II, and basic fibroblast growth factor [2,57]. The GLP-2 analog (teduglutide), EGF, GH, and oral insulin supplementation are the only products assessed so far in humans.

Teduglutide (Gattex) has been approved by the US Food and Drug Administration (FDA) for use in adults with SBS. It has been shown to reduce the need for parenteral nutrition by more than 20% in double-blind randomized adult human trials. Teduglutide induced an increase in plasma citrulline, a marker for enterocyte mass, implicating a healthy reparative effect on the remaining intestinal mucosa of adult patients [58]. Of the 173 patients who received teduglutide in the two phase III clinical trials, seven patients achieved complete independence from PN and/or intravenous fluids [59]. Finally, a pediatric trial of teduglutide is currently underway. Enteral EGF has been studied in pediatric patients with SBS [60]. Five SBS patients had improved nutrient absorption and increased tolerance with enteral feeds. No study yet has demonstrated that EGF has shortened the duration of PN significantly.

Growth hormone is approved in the USA in adults with SBS. Goulet et al. [18] described his own study of high-dose recombinant human growth hormone (rhGH) which allowed PN to be decreased in children with SBS, probably resulting from a significant increase in oral intake as well as net energy and fluid balances. However, the effects of rhGH were not sustained after discontinuation of the treatment for most of the children. They cited a study by Peretti et al. that showed no benefit of rhGH [61].

Finally, a pilot observational study of oral insulin supplementation to pediatric SBS patients resulted in clinical improvement in a subset of patients [61]. Nutrinia has been granted FDA Orphan Designation for NTRA-9620 for SBS. The company is launching a US and European multinational study in neonatal SBS patients to begin late 2016/early 2017. The active ingredient is insulin, which is known to play a key role in maturation and rehabilitation of the GI tract.

5. Laboratory monitoring

In the acute phase – those first two weeks or so, of the initial intestinal injury – it is vital to closely monitor complete blood counts, electrolytes, renal function, blood glucose, and serum triglycerides. It may be necessary to check electrolytes more than once each day to ensure that they remain within normal limits as much as possible given the physiological response post surgery. Renal function may become impaired, hyperglycemia and hypertriglyceridermia may rise due to an inflammatory state or immature metabolism. An upward trend in liver function tests foreshadows dysfunction, exposing evidence of hepatic injury and chronic inflammation. Serum conjugated bilirubin >2 mg/dL after an infant has been on PN for >2 weeks is the usual diagnostic marker for diagnosis of PNAC [21]. As the infant becomes stable and transitions to the recovery or intermediate stage, laboratory monitoring may be decreased to obtaining them no more than two or three times per week, like any other standard PN patient.

Close monitoring of serum zinc, copper, and selenium monthly will help to minimize the potential effects of deficiency such as poor growth, metabolic bone disease, and cardiomyopathy. Monitoring for essential fatty acid deficiency will vary depending on the dose of IVFE, EN, and degree of malabsorption. Measuring fat soluble vitamins A, D, E, and K is important and may be checked every 1, 3, or 6 months, as needed. More frequent monitoring should occur to check for repletion if found to be insufficient/deficient. If the infant develops increased ostomy output, or more frequent loose stools, and is at risk for dehydration, then more frequent electrolyte monitoring is warranted. This stage of recovery might endure for weeks, months, or even years into the late phase of SBS.
Following serum citrulline levels is now widely performed in infants who develop IF to use as a marker for small bowel length, small bowel absorption capabilities, and prognosis for weaning from PN [62–64]. Serum citrulline >19 μmol/L is associated with enteral nutrition tolerance and the ability to be weaned off PN [63].

Short bowel syndrome is a potentially devastating morbidity for the VLBW infant and family with a high risk for mortality. Prevention of injury to the intestine is the ideal, but if and when the problem arises, it is important to have a systematic approach to manage nutrition, and use pharmaceutical strategies and tools to maximize the outcome potential. Safely maximizing PN support by providing adequate macronutrients and micronutrients while minimizing its hepatotoxic effects is the initial postoperative strategy. As the infant stabilizes and starts to recover from that initial injury and/or surgery, a slow and closely monitored enteral nutrition approach should be initiated. Enteral feeds may be complemented with medications and supplements emerging as valuable clinical tools. Engaging a multidisciplinary team of neonatologists, gastroenterologists, pharmacists, skilled clinical nutrition support staff including registered dietitians and nutrition support nurses will facilitate optimizing each and every infant’s outcome.

It is imperative to know the length of the remaining bowel, what segments remain, and if the ICV remains intact. Having that knowledge will help to better understand the infant’s potential for intestinal growth, potential for absorption, and guide the medical nutrition therapy.

Provide parenteral nutrition that supports growth and implement strategies to delay, if not prevent, PNAC. Strategies include reducing IV lipid dose, using alternative IV lipids, decreasing the GIR, and reduce or withdraw hepatotoxic micronutrients.

Enteral nutrition is started as soon as medically safe, and mother’s own milk (or donor human milk) is the ideal source of nutrition. Enteral feeds will need to be fortified to meet the very high nutritional demands of VLBW infants.

Many infants are at risk for essential fatty acid and micronutrient deficiencies and may need sustained electrolyte, vitamin, and mineral supplementation.

In general, infants will be treated with gastric acid suppression medications, motility agents, antibiotics, and ursodeoxycholic acid. The use of these medications, although typically universal, will vary depending on the infant’s course of intestinal rehabilitation.

**Practice points**

- Engage a multidisciplinary team of neonatologists, gastroenterologists, pharmacists, skilled clinical nutrition support staff including registered dietitians and nutrition support nurses will facilitate optimizing each and every infant’s outcome.

- It is imperative to know the length of the remaining bowel, what segments remain, and if the ICV remains intact. Having that knowledge will help to better understand the infant’s potential for intestinal growth, potential for absorption, and guide the medical nutrition therapy.

- Provide parenteral nutrition that supports growth and implement strategies to delay, if not prevent, PNAC. Strategies include reducing IV lipid dose, using alternative IV lipids, decreasing the GIR, and reduce or withdraw hepatotoxic micronutrients.

- Enteral nutrition is started as soon as medically safe, and mother’s own milk (or donor human milk) is the ideal source of nutrition. Enteral feeds will need to be fortified to meet the very high nutritional demands of VLBW infants.

- Many infants are at risk for essential fatty acid and micronutrient deficiencies and may need sustained electrolyte, vitamin, and mineral supplementation.

- In general, infants will be treated with gastric acid suppression medications, motility agents, antibiotics, and ursodeoxycholic acid. The use of these medications, although typically universal, will vary depending on the infant’s course of intestinal rehabilitation.

**Research directions**

- Further research should investigate and potentially create alternative parenteral nutrition products made from less toxic components.

- Further exploration in developing alternative enteral nutrition products and formulas that are derived from human milk, or more closely resemble human milk, and enhance intestinal rehabilitation and overall growth.

- Further research into pharmaceutical products and interventions that complement enteral nutrition therapy.

**Conflict of interest statement**

Olivia Mayer has received speaker honoraria from Prolacta Bioscience, Inc.

**Funding sources**

None.

**References**


---

Please cite this article in press as: Mayer O, Kerner JA, Management of short bowel syndrome in postoperative very low birth weight infants, Seminars in Fetal & Neonatal Medicine (2016), http://dx.doi.org/10.1016/j.siny.2016.08.001